

ATRACURIUM

PRESENTATION:	Ampoules containing Atracurium Besilate 10mg/ml: 2.5ml, 5ml, 25ml.
INDICATION:	Muscle relaxation. Non-depolarising neuromuscular blocking agent with a medium duration of action.
DOSE AND ADMINISTRATION:	Atracurium is administered undiluted as a continuous infusion e.g. 500mg in a 50ml syringe. Ensure sedation is optimised before initiating atracurium infusion. Usual dosage range is 0.65-0.78mg/kg/hour. For example, for a 70kg patient, the recommended rate is 4.5-5.5mls/hour (0.65-0.78mg/kg/hour). Use ideal body weight to calculate doses for overweight patients. Doses can be titrated within the range of 0.27-1.77mg/kg/hr based on patient response.
CONCENTRATION:	10mg/ml
STABILITY:	Physically and chemically stable for 24hours
ADDITIONAL INFORMATION:	In common with all neuromuscular blocking agents, monitoring of neuromuscular function using train-of-four peripheral nerve stimulation is recommended during the use of atracurium in order to individualise dosage requirements.

References

1. Atracurium Besilate 10mg/ml Solution for Injection. Hospira. Summary of Product Characteristics. <https://www.medicines.org.uk/emc/product/3785/smpc>. Accessed: 02/08/23
2. Atracurium besilate, Injectable Medicines Guide. <https://medusa.wales.nhs.uk/IVGuideDisplay.asp?DrugNo=3733> Date published 28/09/22 Date accessed: 01/08/23.
3. Ingrande J, Lemmens HJM. Dose adjustment of anaesthetics in the morbidly obese. British Journal of Anaesthesia, Volume 105, Issue suppl_1, December 2010.
4. British National Formulary. www.bnf.nice.org.uk Last updated 29/11/19. Accessed 02/08/23.

Critical Care Guidelines: Atracurium	
Author: Niall Alexander	
Document Version: 3.0	Authoriser: Lothian Critical Care Directorate QIT Editorial Board
Authorisation date: August 2023	Review date: August 2025